UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000032760
Receipt number R000037364
Scientific Title Effectiveness of Triamcinolone Acetonide to surppress inflammation after eyelid surgery
Date of disclosure of the study information 2018/05/30
Last modified on 2021/09/29 13:51:22

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effectiveness of Triamcinolone Acetonide to surppress inflammation after eyelid surgery

Acronym

Triamcinolone Acetonide for eyelid surgery

Scientific Title

Effectiveness of Triamcinolone Acetonide to surppress inflammation after eyelid surgery

Scientific Title:Acronym

Triamcinolone Acetonide for eyelid surgery

Region

Japan


Condition

Condition

blepharoptosis

Classification by specialty

Ophthalmology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate if intraoperative injection of Triamcinolone acetonide in eyelid surgery can suppress inflammatory reaction safely.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Questionnaire to evaluate the inflammation result
Upper Margin-Refrex distance
Levator function

Key secondary outcomes

complications


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

No treatment

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Inject Triamcinolone Acetonide into orbicularis oculi muscle at the end of the surgery

Interventions/Control_2

Not to Inject Triamcinolone Acetonide into orbicularis oculi muscle at the end of the surgery

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

100 years-old >

Gender

Male and Female

Key inclusion criteria

Patient who needs both blepharoptosis repair simultaneously

Key exclusion criteria

Ongoing infection, steroid resopnder, Glaucoma, Uncontrolled Diabetes, history of trauma or surgery on face

Target sample size

50


Research contact person

Name of lead principal investigator

1st name Ikeda
Middle name
Last name Tsunehiko

Organization

Osaka Medical College

Division name

Ophthalmology

Zip code

5698686

Address

2-7 Daigakumachi Takatsuki city, Osaka

TEL

0726831221

Email

tikeda@osaka-med.ac.jp


Public contact

Name of contact person

1st name Mimura
Middle name
Last name Masashi

Organization

Osaka Medical College

Division name

Ophthalmology

Zip code

5698686

Address

2-7 Daigakumachi Takatsuki city, Osaka

TEL

0726831221

Homepage URL


Email

opt119@osaka-med.ac.jp


Sponsor or person

Institute

Osaka Medical College

Institute

Department

Personal name



Funding Source

Organization

Osaka Medical College

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Osaka Medical College

Address

2-7 Daigakumachi Takatsuki city, Osaka Japan

Tel

0726831221

Email

rinri@osaka-med.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

大阪医科大学附属病院、大阪回生病院


Other administrative information

Date of disclosure of the study information

2018 Year 05 Month 30 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2018 Year 05 Month 30 Day

Date of IRB

2018 Year 04 Month 01 Day

Anticipated trial start date

2018 Year 05 Month 30 Day

Last follow-up date

2021 Year 03 Month 31 Day

Date of closure to data entry

2021 Year 03 Month 31 Day

Date trial data considered complete

2021 Year 06 Month 30 Day

Date analysis concluded

2021 Year 06 Month 30 Day


Other

Other related information



Management information

Registered date

2018 Year 05 Month 29 Day

Last modified on

2021 Year 09 Month 29 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000037364


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name